• In the past week, CONMED Corporation reported second-quarter 2026 results showing sales of US$343.49 million and net income of US$23.07 million, alongside higher earnings per share than a year earlier.
• The company also modestly increased its full-year 2026 net sales guidance range to US$1.36–US$1.37 billion, signaling management’s greater confidence in operational performance.
• Next, we’ll examine how CONMED’s raised full-year sales guidance might influence its existing investment narrative and outlook on profitability.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

CONMED Investment Narrative Recap

To own CONMED, you generally need to believe in steady demand for its minimally invasive surgical tools and the company’s ability to convert that into improving profitability over time. The latest quarter showed only a small uptick in sales but better earnings per share, while the modestly raised 2026 sales guidance suggests the near term catalyst remains execution on margins and operational efficiency. The biggest risk right now is product quality and regulatory scrutiny around AirSeal, which this earnings update does not directly resolve.

The most relevant recent announcement here is the raised full year 2026 net sales guidance to US$1.358 billion to US$1.373 billion, coming alongside higher EPS for both the quarter and first half. While the sales increase versus last year was slight, the combination of tighter profit delivery and a slightly higher revenue bar matters for a story that leans heavily on improved efficiency and better utilization of its existing product portfolio as a key upside driver.

Yet against this improving guidance, the AirSeal recalls highlight an additional product and regulatory risk that investors should be aware of...

CONMED's narrative projects $1.5 billion revenue and $187.6 million earnings by 2029. This requires 3.2% yearly revenue growth and about a $132.8 million earnings increase from $54.8 million today.

Uncover how CONMED's forecasts yield a $39.60 fair value, a 14% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenues of about US$1.6 billion and earnings of roughly US$164 million by 2029, which is a far more upbeat path than the consensus view. When you compare that to the fresh 2026 numbers and the AirSeal recall risk, it shows how differently you and other investors might weigh the upside story against execution and product quality concerns, and why those expectations could shift after this latest update.

Explore 4 other fair value estimates on CONMED - why the stock might be worth 22% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CONMED research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free CONMED research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CONMED's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 55 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.